Det skyldes en række faktorer, herunder at der er flere lægemidler med EF- markedsføringstilladelser, at der for flere af disse lægemidler indhentes tilladelser uden for EU, og muligvis at der er sket en forbedring i indberetningen af bivirkninger uden for EU.
This is due to a number of factors including more medicinal products with Community marketing authorisations, more of these products are gaining authorisations outside the EU and possibly improved reporting of ADRs outside of the EU.